_	

SPO CP 35 POST A (REV 11/2016)

The Ottawa | L'Hôpital Hospital d'Ottawa

PHYSICIAN'S ORDERS Emergency Department, Critical Care, NACU, CCU

Medication Allergies/Reactions	Substances or Food Allergies/Reactions

□ N	one known		
	Admission Orders After A	Altep	lase (tPA)
Init.	Non-Medication	Init.	IV and Medication (Medication, dose, route, frequency)
	Admit to Dr:		IV Therapy: □ NS at mL/h IV
	Clinical Pathway: ☑ Initiate Stroke Clinical Pathway on admission to Stroke Unit/Cohort Neurological assessment: For patients on Stroke Unit ☑ NIHSS q8h and prn if change in neurological status ☑ If greater than or equal to 2 point increase in NIHSS or if other neurological change, notify physician For patients not on Stroke Unit ☑ Neuro vitals with each vital signs Vital signs AND Neuro vitals: ☑ q 15 minutes × 1h ☑ q 30 minutes × 6h ☑ q1h × 17h ☑ Temperature q4h × 24h THEN after 24 hours: ☑ q4h × 24h; then if stable: q8h Oxygen Therapy: ☑ Oxygen Titration Protocol (OTP) to maintain O₂ saturation greater than or equal to 92% Activity: ☐ First 24 hours post Alteplase: mobilize with direct supervision; then AAT ☐ Follow Post Endovascular Treatment For Ischemic Stroke Orders SPO 131 ☐ Other: ☐ Diet: ☑ Standardized swallowing screen ☑ NPO (no food, liquid or PO meds) until standardized swallowing screen form completed ☐ If patient passed screen, start: ☐ Heart healthy ☐ Diabetic ☐ Other: ☐ Plus any pre-admission therapeutic diet and/or texture modification: ☐ If patient failed screen: ☑ NPO ☑ Consult SLP ☑ Repeat swallowing screen within 24h (If SLP unavailable for assessment) If persistent dysphagia after initial 24 hours: ☐ Insert nasoenteric tube to initiate feeding protocol as per Enteral Nutrition		For INITIAL 24 hours following Alteplase infusion NO anticoagulants: apixaban, dabigatran, dalteparin, enoxaparin, fondaparinux, heparin, rivaroxaban, tinzaparin, warfarin NO antiplatelets: ASA, ASA-dipyridamole (Aggrenox), clopidogrel, prasugrel, ticagrelor, ticlopidine 24 hours AFTER Alteplase infusion Following completion of 24-hour follow-up CT head: Call Neurology Physician and ask whether anti-thrombotics may be safely started. Antiplatelet and DVT prophylaxis therapy anticipated to start on: DATE: TIME: After approval by Neurologist, initiate: ASA:
	Policies		
	Management of Angioedema for the Initial	24 h	
	If evidence of angioedema, initiate pharmacological treatment. If severe swelling or airway compromise, call Anesthesia and Respiratory Therapy STAT for airway management.		✓ Diphenhydramine 50 mg IV STAT THEN q4h prn × 24l AND ✓ Ranitidine 50 mg IV STAT THEN q8h prn × 24h AND If severe: ☐ Methylprednisolone 40 mg IV q8h prn × 24h Avoid epinephrine, unless hypotension or impending airway compromise

1-CHART

2-PHARMACY

Patier	nt:		Chart No	
Init.	Non-Medication	Init.	IV and Medication (Medication, dose, route, frequency)	

Init.		Non-Medication	1	Init.	IV and Medication (Medication, dose, route, frequency)
		Assessment			Management of Blood Pressure
	Avoid IM injectio	ng for 24 hours then re			Target systolic BP is less than 185 mmHg and diastolic BP less than 110 mmHg. If systolic BP greater than 185 mmHg OR diastolic BP greater than 110 mmHg for 2 or more readings taken 10 minutes apart: call physician and give the agent as selected below.
		endovascular procedure			Physician to consider one of the following IV agents, as clinically indicated:
	Post Endovascu Orders SPO 131	ular Treatment For Is	eatment For Ischemic Stroke lioedema with each sets of vital signs		If heart rate greater than 50 bpm AND if no significant asthma, physician to consider: ☐ Labetalol 10 mg IV over 2 minutes
	for 24 hours post		acii sets di vital siglis		THEN Repeat q 10 minutes prn to maintain target BP
	Call Physician: If evidence of any of	the following: ter than 185 mmHg or	less than 110 mmHn		Maximum dose 300 mg in 24 hours Administer IV direct undiluted ALERT — Cardiac monitoring Continuous blood pressure monitoring
	☑ Diastolic BP grea ☑ Oral or tympanic	ater than 110 mmHg or temperature greater tha	less than 60 mmHg an 37.5° C		OR If Labetalol contraindicated, or if patient not on cardiac monitor, physician to consider: Hydralazine 10 mg IV over 1 minute
	Respiration rate g	nan 50 bpm or evidence greater than 24 per min oedema (hemilingual, p ess bilaterally); start m	oharyngeal swelling		THEN Repeat q 10 minutes prn to maintain target BP Maximum dose 40 mg in 4 hours Administer IV direct in 20 mL NS ALERT – Continuous blood pressure monitoring
					OR □ Enalaprilat 0.625 mg IV infusion over 15 minutes THEN 0.625 mg IV q6h prn to maintain target BP
		ire bloodwork within 24 n be performed after 6 l			Dilute each dose in 50 mL NS and infuse over 15 minutes
	Alteplase.				Treatment of Fever, Pain, Nausea
	□ CBC □ Na, K □ PTT □ INR □ ALP, AST, ALT, GG	G, CI, urea, creatinine, g ☐ INR daily GT, T Bili			Antipyretics, Analgesics: ☐ Acetaminophen 325–650 mg PO/PR q4h prn for temperature greater than 37.5° C or pain Antiemetics:
	☐ If no known diabe q12h × 48h	etes: Glucose by point	of care testing (POCT)		☐ Ondansetron 8 mg PO OR 4 mg IV q6h prn
	✓ Notify Physic Other:	cian if blood glucose gr	eater than 10 mmol/L		DimenhyDRINATE (Gravol) 25 mg PO/IV q4h prn OR 50 mg PO/IV q4h prn
	ECG (if not perfo		_		Other Medication:
		24 hours post Alteplas			☐ Statin Statin If known diabetes – Physician to complete SPO 215 Subcutaneous Insulin
	Canadian Best Practice	, remove before MRI) Recommendations for St I suspected and confirmed			Administration
	If CTA not performed	d: 🗖 MRA 🗖 C	arotid Doppler		
	If cardioembolic stro	oke suspected: Holter Monitor			
	For General Cam following referral	PT 1 SLP 1 pus only – Physician h forms:	SW Dietitian as completed the		
		to complete AlphaFIM [©] on for both campuses	on or before		
Date (yyyy/mm/dd)	Time	Physician (printed)	1	Signature (Physician)
Date (noted)	Time	Processed by		Signature (Nurse)

SPO CP 35 POST A 2-2